Alivecor makes more waves in heart health tracking
Last month, heart health tracking company Alivecor received further FDA clearance for its 6-lead consumer ECG. While ECG monitoring has grown in popularity with wearable devices from Fitbit, Apple, and other companies, Alivecor’s KardiaMobile 6L uses three electrodes to provide a substantially more informative scan. The device, with just 30 second scans, can provide physicians data to diagnose arrhythmia such as bradycardia, tachycardia, and atrial fibrillation.
KardiaMobile 6L is still in a pre-order phase on Alivecor’s website, but hype for the device is already growing. Last week, the company announced a partnership with Best Buy that will put the device on shelves in 800 stores. While this indicates early commercial acceptance of the device, Alivecor has continued to invest in the technology, having applied for 14 ECG and mobile health related patents in the last two years alone, adding to their quickly growing portfolio, including four issued patents in AI Biotech / Diagnostics.
Related Posts
Cala Health Claims to Have the only Patented Neurostimulation for Essential Tremor Treatment. The Patent Data Disagrees
Cala Health has figured out that innovations backed by patents make them exponentially more valuable in the marketplace. However, in a zest…
Capital One is Investing in AI Biotech? What’s in their wallet?
In the past 18 months, Capital One has expanded past its usual banking activities, and begun exploring the AI Biotech Sector. But do they…
Google AI Reinvents Speech Recognition. Who will follow?
There is no doubt that the big 5 tech companies (Apple, Amazon, Google, Facebook, and Microsoft) have developed massive IP portfolios in…